Because of the recent studies that show the implications of mutations from other predisposing genes (e.g., PALB2, CHEK2, ATM, RAD51C, RAD51D, BRIP1, etc.)in these types of cancers and also the association of the BRCA1 and BRCA2 mutations in other types of cancers, it is necessary to extend the panel of genes tested and the types of cancer (e.g., pancreatic cancer, prostate cancer). This evidence concerns the gene BRCA1 and prostate carcinoma.